TargetMol

Bromotetrandrine

Product Code:
 
TAR-T26911
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T26911-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26911-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26911-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Bromotetrandrine is an P-glycoprotein inhibitor, which were developed and coadministered with chemotherapeutic drugs to overcome the effect of efflux pumps thus enhancing the chemosensitivity of therapeutics.
CAS:
62067-29-2
Formula:
C38H41BrN2O6
Molecular Weight:
701.658
Purity:
0.98
SMILES:
[H][C@]12Cc3ccc(Oc4cc(C[C@]5([H])N(C)CCc6c(Br)c(OC)c(OC)c(Oc7cc1c(CCN2C)cc7OC)c56)ccc4OC)cc3

References

1. Zheng L, Qing YP, Xu N, Yu Q, Wang Y, Wang FP, Li ZY. Pharmacokinetics and safety of bromotetrandrine (BrTet, W198) after single-dose intravenous administration in healthy Chinese volunteers. J Clin Pharm Ther. 2010 Feb;35(1):113-9. doi: 10.1111/j.1365-2710.2009.01075.x. PubMed PMID: 20175820. 2. Song N, Zhang S, Li Q, Liu C. Liquid chromatographic/mass spectrometry assay of bromotetrandrine in rat plasma and its application to pharmacokinetic study. Biomed Chromatogr. 2009 Jun;23(6):623-9. doi: 10.1002/bmc.1163. PubMed PMID: 19277964. 3. Cao X, Luo J, Gong T, Zhang ZR, Sun X, Fu Y. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo. Mol Pharm. 2015 Jan 5;12(1):274-86. doi: 10.1021/mp500637b. PubMed PMID: 25469833. 4. Luo JW, Zhang T, Zhang Q, Cao X, Zeng X, Fu Y, Zhang ZR, Gong T. A novel injectable phospholipid gel co-loaded with doxorubicin and bromotetrandrine for resistant breast cancer treatment by intratumoral injection. Colloids Surf B Biointerfaces. 2016 Apr 1;140:538-47. doi: 10.1016/j.colsurfb.2015.11.029. PubMed PMID: 26628333.